British Journal of Haematology最新文献_第4页

Quality and duration of responses with mogamulizumab in cutaneous T-cell lymphomas: Insights into long-lasting outcomes. 莫加珠单抗治疗皮肤t细胞淋巴瘤的质量和持续时间：对长期结果的见解

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2025-09-14 DOI: 10.1111/bjh.70161

Alessandro Broccoli, Lisa Argnani, Alessandro Pileri, Camilla Mazzoni, Benedetta Sordi, Nicola Pimpinelli, Paolo Fava, Pietro Quaglino, Elsa Pennese, Tommasina Perrone, Andrea Bernardelli, Carlo Visco, Miriam Teoli, Leonardo Flenghi, Adalberto Ibatici, Cesare Massone, Pier Luigi Zinzani

引用次数: 0

Systemic immune-inflammation index and pan-immune value as prognostic indicators of clinical outcomes in mycosis fungoides: A retrospective cohort study. 系统性免疫炎症指数和泛免疫价值作为蕈样真菌病临床结局的预后指标：一项回顾性队列研究。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2025-09-14 DOI: 10.1111/bjh.70151

Joon Min Jung, Myoung Eun Choi, Ik Jun Moon, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Woo Jin Lee

{"title":"Systemic immune-inflammation index and pan-immune value as prognostic indicators of clinical outcomes in mycosis fungoides: A retrospective cohort study.","authors":"Joon Min Jung, Myoung Eun Choi, Ik Jun Moon, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Woo Jin Lee","doi":"10.1111/bjh.70151","DOIUrl":"https://doi.org/10.1111/bjh.70151","url":null,"abstract":"Blood inflammatory markers may provide prognostic insights but remain underexplored in mycosis fungoides (MF). To evaluate the prognostic significance of baseline blood inflammatory markers, including the neutrophil-to-lymphocyte ratio (NLR), eosinophil-to-lymphocyte ratio (ELR), monocyte-to-lymphocyte ratio (MLR), pan-inflammation value (PIV) and systemic immune-inflammation index (SII), in MF. This retrospective cohort study included MF patients diagnosed between 1997 and 2024 at a tertiary medical centre. Markers were analysed in relation to MF stage, morphology, overall survival (OS) and progression-free survival (PFS). Among 195 patients, all markers were significantly elevated in advanced-stage MF compared to early-stage MF. Marker levels generally increased from patch to tumour-stage MF but did not distinguish erythrodermic MF from tumour MF. All markers were associated with poor survival outcomes in univariable analysis. However, in multivariable analysis, only PIV and SII independently associated with poor OS and PFS. Patients with high PIV or SII were more likely to exhibit poor prognostic factors, including advanced stage, head and neck involvement and elevated serum lactate dehydrogenase levels, and experienced more frequent disease progression during follow-up. Single-centre retrospective design. Baseline PIV and SII can be significant prognostic markers in MF, offering enhanced risk stratification and guiding clinical management.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145062906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment. 内皮活化和应激指数（EASIX）作为预测ruxolitinib治疗类固醇难治性急性移植物抗宿主病失败的生物标志物

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2025-09-14 DOI: 10.1111/bjh.70146

Sergio Rodriguez-Rodriguez, Nihar Desai, Carol Chen, Kareem Jamani, Catherine Sohier-Pohier, Christopher Lemieux, Jennifer White, Mohamed Elemary, Michael Kennah, Tommy Alfaro Moya, Eshrak Al-Shaibani, Igor Novitzky-Basso, Ivan Pasic, Arjun Datt Law, Fotios V Michelis, Auro Viswabandya, Rajat Kumar, Jonas Mattsson, Dennis Dong Hwan Kim

{"title":"Endothelial activation and stress index (EASIX) as a biomarker to predict ruxolitinib failure for steroid-refractory acute graft-versus-host disease treatment.","authors":"Sergio Rodriguez-Rodriguez, Nihar Desai, Carol Chen, Kareem Jamani, Catherine Sohier-Pohier, Christopher Lemieux, Jennifer White, Mohamed Elemary, Michael Kennah, Tommy Alfaro Moya, Eshrak Al-Shaibani, Igor Novitzky-Basso, Ivan Pasic, Arjun Datt Law, Fotios V Michelis, Auro Viswabandya, Rajat Kumar, Jonas Mattsson, Dennis Dong Hwan Kim","doi":"10.1111/bjh.70146","DOIUrl":"https://doi.org/10.1111/bjh.70146","url":null,"abstract":"Steroid-refractory acute graft-versus-host disease (SR-aGvHD) remains a significant challenge after haematopoietic cell transplantation (HCT). While ruxolitinib (RUX) has shown efficacy for SR-aGvHD, failure predictors are poorly defined. We assessed 78 patients from six Canadian centres who received RUX for SR-aGvHD. Failure-free survival (FFS) was the primary end-point. Endothelial activation and stress index (EASIX) scores were calculated at defined time points, dichotomized using recursive partitioning. A risk score for RUX failure was developed based on key variables. At RUX initiation, 76% of patients had grade 3-4 aGvHD. The best overall response rate was 75%; 58% experienced RUX failure, while the 6-month FFS was 25.7%. EASIX gradually increased over time even after RUX (p < 0.001). Patients with high EASIX at RUX ≥1.11 had a lower FFS at 6 months (17%) than the patients with low EASIX (54%) (hazard ratio [HR] 2.75 [95%CI 1.23-6.15], p = 0.014). A three-factor RUX failure risk score-gut aGvHD, grade 4 aGvHD and high EASIX at RUX start-stratified patients by 6-month FFS rates: 85.7%, 28.0% and 11.0% for score 0 (n = 28), 1 (n = 25) and ≥2 (n = 34) (HR 2.25[1.42-3.55], p < 0.001). High EASIX can predict the risk of RUX failure in addition to gut aGvHD and grade 4 aGvHD. We propose to add other therapeutic interventions to RUX therapy pre-emptively to high EASIX patients.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145062894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improved outcomes in elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol-A prospective study. 采用儿科方案改善老年急性淋巴细胞白血病患者的预后-一项前瞻性研究

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2025-09-14 DOI: 10.1111/bjh.70159

P Quist-Paulsen, L Horvei, J Dalgaard, M Moksnes, A L Eilertsen, M Paulson, N A Azrakhsh, W Majeed, H S Wik

{"title":"Improved outcomes in elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol-A prospective study.","authors":"P Quist-Paulsen, L Horvei, J Dalgaard, M Moksnes, A L Eilertsen, M Paulson, N A Azrakhsh, W Majeed, H S Wik","doi":"10.1111/bjh.70159","DOIUrl":"https://doi.org/10.1111/bjh.70159","url":null,"abstract":"Population data have shown that the prognosis for elderly patients with acute lymphoblastic leukaemia (ALL) is poor, even in the modern era and despite improvements in the outcome for younger patients. In this Norwegian prospective population-based study, the feasibility and effectiveness of a paediatric-based regimen in newly diagnosed patients above 65 years of age with ALL were assessed. Patients who were Philadelphia chromosome (Ph) negative were assigned to unmodified doses of pegylated asparaginase starting on day 30, while Ph-positive patients were treated with imatinib. For frail patients, dose reductions were allowed at the discretion of the treating physician. A total of 52 patients were enrolled, 32 of whom were Ph negative. The median age was 70 years (range 65-82). Forty-nine attained remission, of which four did not receive further treatment and died. Six patients died while in remission and three died from a second malignancy. Among the remaining 36 patients, only six relapsed. The 2-year and 5-year overall survival rates, with a median follow-up of 3.2 years (Interquartile range 1.3-6.3), were 0.60 (95% confidence interval 0.46-0.74) and 0.50 (0.34-0.66) respectively. In conclusion, this paediatric-based protocol was well tolerated and effective, with low relapse rates and 50% long-term survival.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145062941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia. 改良移植后环磷酰胺与粒细胞集落刺激因子/抗胸腺细胞球蛋白方案在重度再生障碍性贫血替代供体移植中的临床结果

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2025-09-14 DOI: 10.1111/bjh.70133

Liangliang Wu, Ming Zhou, Xiaowei Chen, Wenjian Mo, Ruiqing Zhou, Yumiao Li, Caixia Wang, Shilin Xu, Fangfang Yang, Yuling Zhang, Xiaoqing He, Xinxin Li, Shunqing Wang, Yuping Zhang

{"title":"Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.","authors":"Liangliang Wu, Ming Zhou, Xiaowei Chen, Wenjian Mo, Ruiqing Zhou, Yumiao Li, Caixia Wang, Shilin Xu, Fangfang Yang, Yuling Zhang, Xiaoqing He, Xinxin Li, Shunqing Wang, Yuping Zhang","doi":"10.1111/bjh.70133","DOIUrl":"https://doi.org/10.1111/bjh.70133","url":null,"abstract":"Post-transplantation cyclophosphamide (PTCy) and granulocyte colony-stimulating factor/anti-thymocyte globulin (G-CSF/ATG) are established protocols for alternative donor haematopoietic stem cell transplantation (AD-HSCT) in severe aplastic anaemia (SAA). A modified PTCy (mPTCy) regimen, featuring increased ATG dosing (2.0 mg/kg/day, days -5 to -3) and reduced cyclophosphamide (40 mg/kg/day, days +3 and +4), showed promising outcomes in a prospective study but lacks direct comparison with G-CSF/ATG. This post hoc comparative analysis utilized data from our prospective mPTCy cohort (ChiCTR2000038297, n = 101, plus a 1-year protocol-consistent enrolment extension, n = 56) and a retrospective historical G-CSF/ATG cohort (n = 140) to compare outcomes in AD-HSCT. Both protocols showed similar incidences of engraftment, graft failure and overall survival. Multivariate analysis confirmed reduced risks of 100-day grade II-IV acute graft-versus-host disease (GVHD) (hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.26-0.71, p < 0.001) and 2-year chronic GVHD (HR 0.33, 95% CI 0.17-0.65, p = 0.001), and improved 2-year GVHD, relapse/rejection-free survival (GRFS; HR 0.51, 95% CI 0.32-0.83, p = 0.007) with mPTCy versus G-CSF/ATG. Subgroup analysis revealed superior outcomes with mPTCy in haploidentical-HSCT, while outcomes were comparable between protocols in unrelated donor HSCT. These findings suggest mPTCy superiority over G-CSF/ATG in SAA patients undergoing AD-HSCT, especially haploidentical-HSCT, by reducing GVHD and improving GRFS.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145062917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pre-infusion cytomegalovirus T-cell immunity for predicting the risk of virus DNAemia in patients undergoing chimeric antigen receptor T-cell therapies. 在接受嵌合抗原受体t细胞治疗的患者中，预输注巨细胞病毒t细胞免疫预测病毒dna血症的风险。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2025-09-12 DOI: 10.1111/bjh.70162

Eliseo Albert, Rafael Hernani, Estela Giménez, Ester Colomer, Ana Benzaquén, José Luis Piñana, Carlos Solano, David Navarro

引用次数: 0

A decade of pharmacovigilance in France: Immune checkpoints join the list of usual suspects for drug-induced immune haemolytic anaemia. 法国十年的药物警戒：免疫检查点加入了药物引起的免疫性溶血性贫血的通常嫌疑人名单。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2025-09-12 DOI: 10.1111/bjh.70152

Guillaume Brenac, Anne Dautriche, Romane Freppel, Anthony Facile, Bruno Revol, Mathilde Beurrier, Bernard Bonnotte, Sylvain Audia

引用次数: 0

'Raise the Bar', a Canadian intervention to combat disparities in the recognition and management of iron deficiency: Development of the intervention, feasibility and implementation. “提高标准”，加拿大的一项干预措施，旨在消除对缺铁的认识和管理方面的差距：干预措施的发展、可行性和实施。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2025-09-12 DOI: 10.1111/bjh.70150

Grace H Tang, Zoe Phillips, Susan Poutanen, Paul Yip, Davor Brinc, Elaine Goh, Mark Cheung, Menaka Pai, Curtis Oleschuk, Daniel Beriault, Cristiana Stefan, Larissa Matukas, David Good, Angela Weyand, Jillian Baker, Mark Crowther, Jacob Cogan, Nicole White-AlHabeeb, Zahraa Mohammed-Ali, Miranda Wozniak, Dana Nyholt, Sonieya Nagarajah, Carine Bekdache, Hui Li, Hasan Ghaffar, Kika Veljkovic, Uvaraj Uddayasankar, Lusia Sepiashvili, Peter Catomeris, Rita Selby, Michelle Sholzberg

引用次数: 0

The British Journal of Haematology celebrates its 70th birthday. Part one: Malignant haematology 2018-2024. 《英国血液学杂志》庆祝70岁生日。第一部分：恶性血液学2018-2024。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2025-09-12 DOI: 10.1111/bjh.70153

Arnold Ganser

引用次数: 0

MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy. 接受CD19 CAR - t细胞治疗的大b细胞淋巴瘤患者的mtv引导放疗桥接。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2025-09-11 DOI: 10.1111/bjh.70137

Andrea Kuhnl, S Bouziana, S F Barrington, S Galani, T Menne, M Northend, L Stevens, S Kamat, W Osborne, R Johnson, E Kumar, R Sanderson, P E M Patten, R Benjamin, J Frew, R Prestwich, J L Brady, N G Mikhaeel

引用次数: 0